Introduction
Arthritis is a common chronic condition that affects millions of people worldwide. It can cause pain, swelling, and stiffness in the joints, making everyday tasks difficult.
Overview of Xeljanz
Xeljanz is the brand name for the drug tofacitinib, which belongs to a class of medications known as Janus kinase (JAK) inhibitors. It is approved for the treatment of various forms of arthritis, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Mechanism of Action
Xeljanz works by inhibiting Janus kinase enzymes, specifically JAK1 and JAK3. These enzymes play a crucial role in the inflammatory process that contributes to arthritis symptoms.
Clinical Efficacy
Numerous clinical studies have demonstrated the efficacy of Xeljanz in reducing joint pain and swelling in patients with arthritis. It has also been shown to improve physical function and quality of life for individuals with arthritis.
Side Effects and Considerations
While Xeljanz is generally well-tolerated, it can have potential side effects, including an increased risk of infections and gastrointestinal issues. It is important for patients to discuss the benefits and risks of Xeljanz treatment with their healthcare provider.